Cutaneous reactions to cardiovascular drugs.
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D003000:Clonidine / Q000009:adverse effects; D003647:Debrisoquin / Q000009:adverse effects; D004071:Digitalis Glycosides / Q000009:adverse effects; D003875:Drug Eruptions / Q000209:etiology*; D004976:Ethacrynic Acid / Q000009:adverse effects; D005665:Furosemide / Q000009:adverse effects; D006145:Guanethidine / Q000009:adverse effects; D006801:Humans; D006830:Hydralazine / Q000009:adverse effects; D008628:Mercury / Q000009:adverse effects; D008750:Methyldopa / Q000009:adverse effects; D005996:Nitroglycerin / Q000009:adverse effects; D010417:Pentaerythritol Tetranitrate / Q000009:adverse effects; D011342:Procainamide / Q000009:adverse effects; D011802:Quinidine / Q000009:adverse effects; D013843:Thiazines / Q000009:adverse effects
D000319:Adrenergic beta-Antagonists; D004071:Digitalis Glycosides; D013843:Thiazines; D010417:Pentaerythritol Tetranitrate; D006830:Hydralazine; D008750:Methyldopa; D005665:Furosemide; D008628:Mercury; D005996:Nitroglycerin; D011802:Quinidine; D011342:Procainamide; D004976:Ethacrynic Acid; D003000:Clonidine; D003647:Debrisoquin; D006145:Guanethidine